TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9639376

Group type: EXPERIMENTAL
Intervention: NEP inhibitor candoxatrilat (125 nmol/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: NEP inhibitor thiorphan (30 nmol/min) after placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: NEP inhibitor thiorphan (30 nmol/min) after enalapril (20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NEP inhibitor thiorphan (30 nmol/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endothelin ETA antagonist BQ‐123 (100 nmol/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined thiorphan and BQ‐123
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NEP inhibitor thiorphan (30 nmol/min) in hypertensive patients
Number of subjects: 30
Study: 8079106

Group type: EXPERIMENTAL
Intervention: Olsalazine (2 g daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mesalazine (2 g or 6 g daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (pre-medication)
Number of subjects: 13
Study: 2535239

Group type: EXPERIMENTAL
Intervention: HEVAC B
Number of subjects: 591

Group type: COMPARATOR
Intervention: GCC VAC
Number of subjects: 591

Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 591
Study: 1269844

Group type: EXPERIMENTAL
Intervention: Multiple daily injections
Number of subjects: 42

Group type: COMPARATOR
Intervention: Single daily injections
Number of subjects: 42
Study: 31876630

Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30969032

Group type: EXPERIMENTAL
Intervention: Combined 8.3 mg Nestorone® and 62.5 mg Testosterone gel (Nes-T)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 62.7 mg Testosterone gel
Number of subjects: 44
Study: 28609307

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 120
Study: 25553939

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 1498
Study: 22505302

Group type: EXPERIMENTAL
Intervention: Disposcope endoscope (DE)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 68
Study: 21527360

Group type: EXPERIMENTAL
Intervention: Bosentan treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18972729

Group type: EXPERIMENTAL
Intervention: Spreading moxibustion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 56
Study: 16523337

Group type: EXPERIMENTAL
Intervention: Paclitaxel-cisplatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gemcitabine-cisplatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paclitaxel-gemcitabine
Number of subjects: 24
Study: 12511540

Group type: EXPERIMENTAL
Intervention: BNP infusion (60, 120, and 180 pmol/min)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BNP infusion (180 pmol/min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study: 10759711

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (BMT)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Unrelated donor BMT
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Related donor BMT
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Overall for all patients
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Children relapsing in the bone marrow within 2 years of diagnosis
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Children relapsing without bone marrow involvement > 2.5 years from diagnosis
Number of subjects: 256
Study: 8965117

Group type: EXPERIMENTAL
Intervention: Copolymer 1 (Copaxone) 20 mg daily subcutaneous injection for at least 1 year
Number of subjects: 857

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Copolymer 1 (Copaxone)
Number of subjects: 857
Study: 1814318

Group type: EXPERIMENTAL
Intervention: Oral magnesium-lactate-citrate for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (30 mmol daily for 7 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Reference group (patients without known predisposition to magnesium deficiency)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 40
Study: 6362459

Group type: EXPERIMENTAL
Intervention: Prolonged reduction in alcohol consumption
Number of subjects: 93

Group type: COMPARATOR
Intervention: Maintenance or increase of alcohol consumption
Number of subjects: 93
Study: 31924120

Group type: EXPERIMENTAL
Intervention: Low-energy ESWT
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 31
Study: 30496533

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment for Pain (CBT-P)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 113
Study: 27974398

Group type: EXPERIMENTAL
Intervention: VPM1002
Number of subjects: 48

Group type: COMPARATOR
Intervention: BCG Danish strain
Number of subjects: 48
Study: 26126062

Group type: EXPERIMENTAL
Intervention: Nursing case management
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 24380637

Group type: EXPERIMENTAL
Intervention: Run-off CTA with 40 mL of contrast medium (injection rate of 6 mL/s)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Run-off CTA with optimized scan times based on double-level test bolus technique
Number of subjects: 92
Study: 22284284

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hard viscoelastic wafer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Soft viscoelastic wafer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19527338

Group type: EXPERIMENTAL
Intervention: TA-loaded lipid nanocarriers (TA-LNCs) incorporated into a hydrophilic gel and foam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saturated TA solution in silicon oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TA-loaded lipid nanocarriers (TA-LNCs)
Number of subjects: 0
Study: 17475733

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (augmentation with citalopram)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Medication augmentation (sustained-release bupropion or buspirone)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Switch to cognitive therapy
Number of subjects: 404

Group type: COMPARATOR
Intervention: Switch to another antidepressant (sertraline, sustained-release bupropion, or extended-release venlafaxine)
Number of subjects: 404
Study: 15064269

Group type: EXPERIMENTAL
Intervention: Alfentanil at 75 ng*mL(‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alfentanil at 0 ng*mL(‐1) (Group 0)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil at 25 ng*mL(‐1) (Group 25)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil at 50 ng*mL(‐1) (Group 50)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil at 75 ng*mL(‐1) (Group 75)
Number of subjects: 40
Study: 12221346

Group type: EXPERIMENTAL
Intervention: Early management by the occupational physician
Number of subjects: 120

Group type: COMPARATOR
Intervention: Management by the worker's supervisor
Number of subjects: 120
Study: 11283429

Group type: EXPERIMENTAL
Intervention: AN-TS (eight 10-s all-out tests every 5 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SMT (one 60-s all-out test)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AN-TS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SMT
Number of subjects: 12
Study: 9431285

Group type: EXPERIMENTAL
Intervention: Parent-child auto-tutorial nutrition education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling by a dietitian
Number of subjects: 0
Study: 8507125

Group type: EXPERIMENTAL
Intervention: 10 g of K8515 ingested in a prehydrated form three times a day with meals
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 6.7 g of K8515 three times a day
Number of subjects: 22
Study: 3327845

Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fenoterol (5 mg)
Number of subjects: 22
Study: 27669182

Group type: EXPERIMENTAL
Intervention: Jump Shrug (JS) at 30% of 1RM HPC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Jump Shrug (JS) at 50% of 1RM HPC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hang Power Clean (HPC) at 30% of 1RM HPC
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hang Power Clean (HPC) at 50% of 1RM HPC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Joint-averaged propulsive phase duration at 30% of 1RM HPC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Joint-averaged peak concentric power at 70% of 1RM for HPC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Joint-averaged peak concentric power at 30%-50% of 1RM for JS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Load-averaged peak knee and ankle concentric joint powers during JS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Load-averaged power of all joints during HPC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Load-averaged power of hip and knee joints during JS
Number of subjects: 15
Study: 27121865

Group type: EXPERIMENTAL
Intervention: Tailored cognitive-behavioral resilience training (TCBRT)
Number of subjects: 14
Study: 24231560

Group type: EXPERIMENTAL
Intervention: Group 1 (prednisolone 2mg/kg/day over 4 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Group 2 (prednisolone 4 mg/kg/day over 1 week and 2mg/kg/day for the next 3 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Group 3 (prednisolone 4 mg/kg/day over 4 weeks)
Number of subjects: 63
Study: 22402793

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patch (Lidoderm(®), Endo Pharmaceuticals)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 72
Study: 20097702

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg/day with atorvastatin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo with atorvastatin
Number of subjects: 135
Study: 19069460

Group type: EXPERIMENTAL
Intervention: Bismuth tri‐potassium di‐citrate (De-Nol) 120 mg thrice daily with meteospasmyl (spasmolytic and antifoaming agent) for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aluminium phosphate with meteospasmyl (1 capsule thrice daily) for 3 weeks
Number of subjects: 30
Study: 16162940

Group type: EXPERIMENTAL
Intervention: Simvastatin, 80 mg/day
Number of subjects: 0
Study: 14702121

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg/day for 10 days
Number of subjects: 318

Group type: COMPARATOR
Intervention: Clarithromycin 1000 mg/day for 10 days
Number of subjects: 318
Study: 10394976

Group type: EXPERIMENTAL
Intervention: 600 mg CPFX plus 600 mg CAM (combination group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 600 mg CPFX (CPFX group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg CPFX plus 600 mg CAM (combination group) in patients with an indwelling catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: 600 mg CPFX (CPFX group) in patients with an indwelling catheter
Number of subjects: 0
Study: 8785404

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (800 to 3200 mg/day) for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no acyclovir)
Number of subjects: 32
Study: 1804644

Group type: EXPERIMENTAL
Intervention: Ro 23‐6152 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ro 23‐6152 80 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ro 23‐6152 10 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29516341

Group type: EXPERIMENTAL
Intervention: Strongest Families™ Parenting the Active Child (12-week parent training program delivered via written material, skill-based videos, and telephone coaching)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Strongest Families™ Parenting the Active Child
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both conditions (Strongest Families™ and Usual Care)
Number of subjects: 172
Study: 27721230

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1800 mg daily for 4 months)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25509696

Group type: EXPERIMENTAL
Intervention: Loaded calcitriol regimen
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Titrated calcitriol regimen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Calcium gluconate intravenous use
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hypocalcemia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Duration of hospital stay
Number of subjects: 25
Study: 21963422

Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 19717476

Group type: COMPARATOR
Intervention: Salmeterol (Salm)
Number of subjects: 6232

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 6232

Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone propionate combination (SFC)
Number of subjects: 6232

Group type: COMPARATOR
Intervention: SFC
Number of subjects: 6232
Study: 18847425

Group type: EXPERIMENTAL
Intervention: Combined treatment with an ACE inhibitor (perindopril) and a diuretic (indapamide) in fixed doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct renin inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive, multifactorial and multidisciplinary management
Number of subjects: 0
Study: 17145988

Group type: EXPERIMENTAL
Intervention: Same-day home discharge and abciximab bolus only (group 1)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Overnight hospitalization and abciximab bolus and infusion (group 2)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1005
Study: 12691286

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Digoxin and diuretics
Number of subjects: 17
Study: 11174874

Group type: EXPERIMENTAL
Intervention: Estrogen/progestin therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no hormone replacement therapy)
Number of subjects: 100
Study: 9179430

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (200 micrograms once daily for 14 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo nasal spray (for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 20
Study: 8255415

Group type: EXPERIMENTAL
Intervention: CT group (cold temperature of 5 degrees C for 20 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5HT group (5HT-1a agonist under normal temperature)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NT group (normal temperature and placebo)
Number of subjects: 0
Study: 3895827

Group type: EXPERIMENTAL
Intervention: 100 ml of cold carbonated water
Number of subjects: 27

Group type: COMPARATOR
Intervention: 100 ml of lukewarm tap water
Number of subjects: 27

Group type: COMPARATOR
Intervention: 25 ml of lukewarm tap water
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Yoghurt
Number of subjects: 27
Study: 31841537

Group type: EXPERIMENTAL
Intervention: K5 BxB mode
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: K5 MC mode
Number of subjects: 15
Study: 29443652

Group type: EXPERIMENTAL
Intervention: Dexamethasone on days 1 to 3 (Arm D3)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Dexamethasone on day 1 and placebo on days 2 and 3 combined with NK1-RA and Palonosetron (Arm D1)
Number of subjects: 396
Study: 27450628

Group type: EXPERIMENTAL
Intervention: Treated fractures in Sierra Leone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Untreated fractures in Sierra Leone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avertable fracture DALYs in Sierra Leone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avertable fracture DALYs in Nepal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investment needed to address excess burden in Sierra Leone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investment needed to address excess burden in Nepal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall opportunity to avert DALYs
Number of subjects: 0
Study: 25382508

Group type: EXPERIMENTAL
Intervention: Autoinoculation therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (excised warty tissue only, no implantation)
Number of subjects: 48
Study: 22584566

Group type: EXPERIMENTAL
Intervention: sHT treatment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 20443153

Group type: EXPERIMENTAL
Intervention: 80% inspired oxygen via PULMANEX Hi‐Ox Mask (10 L/min)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 30% oxygen via nasal cannula (2 L/min)
Number of subjects: 42
Study: 18536191

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20‐60 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Imipramine (50‐150 mg/day)
Number of subjects: 10
Study: 15921059

Group type: EXPERIMENTAL
Intervention: Nutritional counseling by a GP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nutritional counseling by a dietician
Number of subjects: 60
Study: 12462772

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g intravenous single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (intravenous)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of propacetamol and promedol (opioid analgesic)
Number of subjects: 30
Study: 10424186

Group type: EXPERIMENTAL
Intervention: Box features (size, weight, handle features, location on pallet)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inclusion of handles
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Box weight
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Box size
Number of subjects: 10
Study: 7568839

Group type: EXPERIMENTAL
Intervention: Fluoroscopic spot radiographs
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Digital subtraction images
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of digital subtraction and fluoroscopic spot images
Number of subjects: 64
Study: 2188773

Group type: EXPERIMENTAL
Intervention: pyrazinoylguanidine (300 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pyrazinoylguanidine (600 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pyrazinoylguanidine (300 mg b.i.d. for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pyrazinoylguanidine (600 mg b.i.d. for 3 days)
Number of subjects: 0
Study: 6777806

Group type: EXPERIMENTAL
Intervention: 20 mg diazepam (DZ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 20 mg N-desmethyldiazepam (NDDZ)
Number of subjects: 50
Study: 30910531

Group type: EXPERIMENTAL
Intervention: Behavioural intervention plus supplies for syphilis testing and treatment
Number of subjects: 36036

Group type: COMPARATOR
Intervention: Supplies only (control group)
Number of subjects: 36036
Study: 28394858

Group type: EXPERIMENTAL
Intervention: Ultrashort 15-minute incubation ALA followed by blue light PDT with fractional CO2 laser (FxCO2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrashort 30-minute incubation ALA followed by blue light PDT with fractional CO2 laser (FxCO2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrashort 15-minute incubation ALA followed by blue light PDT without fractional CO2 laser (‐FxCO2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrashort 30-minute incubation ALA followed by blue light PDT without fractional CO2 laser (‐FxCO2)
Number of subjects: 0
Study: 26287025

Group type: COMPARATOR
Intervention: Traditional inferior alveolar nerve block (IANB)
Number of subjects: 91

Group type: COMPARATOR
Intervention: IANB with computer-controlled local anesthetic delivery (CCLAD)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intraligamental anesthesia with CCLAD
Number of subjects: 91
Study: 23549522

Group type: EXPERIMENTAL
Intervention: COMT Val/Val alleles
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: COMT Val/Met alleles
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: All patient groups (including COMT Val/Val, Val/Met, and Met/Met)
Number of subjects: 78
Study: 21631324

Group type: EXPERIMENTAL
Intervention: gp100:209‐217(210M) peptide vaccine plus interleukin‐2 (720,000 IU per kilogram of body weight per dose)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Interleukin‐2 alone (720,000 IU per kilogram of body weight per dose)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: gp100:209‐217(210M) peptide vaccine plus interleukin‐2
Number of subjects: 185

Group type: COMPARATOR
Intervention: Interleukin‐2 alone
Number of subjects: 185
Study: 19839745

Group type: EXPERIMENTAL
Intervention: Simultaneous TURBT and TURP (group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Separate sittings for TURBT and TURP (group B)
Number of subjects: 48
Study: 16622705

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (n=11)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Percutaneous resection under CT guidance (n=41)
Number of subjects: 52
Study: 12477759

Group type: EXPERIMENTAL
Intervention: Substance P (1-6 pmol/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurokinin A (6-50 pmol/kg/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance P (highest dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurokinin A (highest dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 10951534

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) for 4 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17